Which neurotransmitter hypothesis of depression proposes a deficiency in monoamines (serotonin, norepinephrine, and dopamine) as the primary neurobiological basis?

Explanation

## Monoamine Hypothesis of Depression **Key Point:** The **monoamine hypothesis** (also called the catecholamine hypothesis or biogenic amine hypothesis) posits that depression results from a deficiency of monoamine neurotransmitters, particularly **serotonin (5-HT)**, **norepinephrine (NE)**, and **dopamine (DA)** in the central nervous system. ### Historical Context and Evidence 1. **Origin:** Proposed in the 1960s following observations that: - Reserpine (depletes monoamines) causes depression - Tricyclic antidepressants and MAOIs (increase monoamines) improve mood 2. **Current understanding:** The hypothesis remains foundational but is now recognized as incomplete—it explains drug action but not the full pathophysiology of depression. ### Monoamine Neurotransmitter Roles in Depression | Neurotransmitter | Associated Symptoms When Deficient | |------------------|------------------------------------| | Serotonin | Mood, anxiety, sleep, appetite regulation | | Norepinephrine | Attention, motivation, arousal, energy | | Dopamine | Motivation, reward, pleasure (anhedonia) | **High-Yield:** This hypothesis directly explains the mechanism of action of all major antidepressant classes: - **SSRIs:** Increase serotonin - **SNRIs:** Increase serotonin and norepinephrine - **TCAs:** Increase norepinephrine and serotonin - **Bupropion:** Increases dopamine and norepinephrine **Mnemonic:** **SND** = Serotonin, Norepinephrine, Dopamine (the three monoamines implicated in depression) ### Limitations of the Hypothesis - Antidepressants increase monoamines within hours, but clinical improvement takes weeks (monoamine depletion does not fully explain the delay) - Not all depressed patients have demonstrable monoamine deficiency - Does not account for genetic, environmental, and psychosocial factors - Newer hypotheses (neuroinflammation, HPA axis dysfunction, neuroplasticity) provide additional insights **Clinical Pearl:** While incomplete, the monoamine hypothesis remains the most clinically useful model for understanding antidepressant pharmacology and is the foundation of psychiatric treatment.